Interaction between TPH1 and GNB3 genotypes and electroconvulsive therapy in major depression

• Published in: Journal of Neural Transmission Vol. 114; no. 4; pp. 461 - 468
• Main Authors: Anttila, S, Huuhka, K, Huuhka, M, Rontu, R, Mattila, K M, Leinonen, E, Lehtimäki, T
• Format: Journal Article
• Language: English
• Published: Austria Springer Nature B.V 01-04-2007
• Subjects: Depressive Disorder, Major - genetics; Depressive Disorder, Major - therapy; Electroconvulsive Therapy; Female; Genotype; Heterotrimeric GTP-Binding Proteins - genetics; Humans; Linkage Disequilibrium; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Treatment Outcome; Tryptophan Hydroxylase - genetics
• ISSN: 0300-9564; 1435-1463
• DOI: 10.1007/s00702-006-0583-6

We studied the association between tryptophan hydroxylase 1 (TPH1) A218C and G-protein beta-3 subunit (GNB3) C825T polymorphisms and treatment response in electroconvulsive therapy (ECT). The sample consisted of 119 patients with major depressive disorder (MDD) and 398 controls. Neither TPH1 nor GNB3 polymorphisms are associated with treatment response. However, subjects carrying TPH1 CC genotype are more likely to belong to the patient sample than to the controls. In female subjects, T-allele of GNB3 polymorphism increases the risk of being a treatment-resistant patient with MDD. Moreover, in females the combination of TPH1 CC and GNB3 CT + TT genotype is associated with an increased risk of belonging to the patient group.